Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MBX-8025 phase 2 study in homozygous familial hypercholesterolemia
NL-OMON42038Phase 2Withdrawn
- Sponsor
- CymaBay Therapeutics
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of seladelpar in homozygous familial hypercholesterolemia (HoFH), sponsored by CymaBay Therapeutics. Primary endpoint: LDL-C. Planned start Jan 2015; status: withdrawn.
02
Drugs
seladelpar
03
Conditions
homozygous familial hypercholesterolemia (HoFH)
Beyond the preview
Go deeper on NL-OMON42038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42038.